AI study “exciting first step”

Artificial intelligence could help guide the post-treatment surveillance of non-small cell lung cancer (NSCLC) patients and improve outcomes as a result, according to a study led by researchers from The Royal Marsden NHS Foundation Trust in collaboration with The Institute of Cancer Research, London, and Imperial College London, which was supported by The Royal Marsden Cancer Charity.

In a world first, the OCTAPUS-AI study, published in the Lancet’s EbioMedicine journal, compared different machine learning models to determine which could most accurately identify NSCLC patients at risk of…